IP Library › Assignment 059810/0102
Patent Assignment
Reel/Frame 059810/0102

Change of Name

Recorded: 2022-04-27 Pages: 7
Assignor
Assignee
SUMITOMO PHARMA ONCOLOGY, INC.
640 MEMORIAL DRIVE, CAMBRIDGE, MASSACHUSETTS, 02139
Covered Properties (65)
Pseudopolymorph of ( - ) -Cis -2-(2 -Chlorophenyl) -5, 7-Dihydroxy-8 [4R- ( 3S-Hydroxy -1-Methyl)Piperidinyl ] -4H -1 -Benzopyran-4-One
Patent: 6,576,647 →
Application: 09/760,589 →
Publication: US 2003/0045551
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 15/524,953 →
Publication: US 2018/0280407
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 15/874,755 →
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Application: 16/382,726 →
Publication: US 2019/0314357
Profiling Peptides and Methods for Sensitivity Profiling
Application: 16/545,916 →
Publication: US 2020/0200737
Methods for Treating Castration-Resistant and Castration-Sensitive Prostate Cancer
Application: 16/706,463 →
Publication: US 2020/0281949
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Application: 16/708,366 →
Publication: US 2020/0276174
Alvocidib Prodrugs Having Increased Bioavailability
Application: 16/727,693 →
Publication: US 2020/0131210
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 16/814,398 →
Publication: US 2021/0052568
Pseudopolymorph of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8(4R-3S-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one
Application: 60/266,307 →
Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the Axl Kinase
Application: 61/471,090 →
PKM2 Modulators and Methods for Their Use
Application: 61/714,659 →
PKM2 Modulators and Methods for Their Use
Application: 61/875,855 →
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 62/077,042 →
Methods to Target Transcriptional Control at Super-Enhancer Regions
Application: 62/150,110 →
Predicting Response to Alvocidib by Mitochondrial Profiling
Application: 62/150,138 →
Alvocidib Prodrugs Having Increased Bioavailability
Application: 62/163,188 →
Combination Therapies for Treatment of Cancer
Application: 62/200,499 →
Alvocidib Prodrugs and Their Use as Protein Kinase Inhibitors
Application: 62/424,255 →
Profiling Peptides and Methods for Sensitivity Profiling
Application: 62/436,221 →
Compositions and Methods for Treating Bcl-2 Inhibitor Insensitive Subjects Using Mcl-1 Inhibitors
Application: 62/557,635 →
Profiling Peptides and Methods for Sensitivity Profiling
Application: 62/562,990 →
PKM2 Activators in Combination with Reactive Oxygen Species for Treatment of Cancer
Application: 62/572,237 →
Materials and Methods for Treating Cancer
Application: 62/653,376 →
Salts of Axl Kinase Inhibitors and Methods of Preparation of the Same
Application: 62/653,394 →
Cyclin-Dependent Kinase Inhibitors in Combination with Tetracyclic Anthracyclines for Treatment of Cancer
Application: 62/657,545 →
Salts of Axl Kinase Inhibitors and Methods of Preparation of the Same
Application: 62/663,146 →
Salts of Axl Kinase Inhibitors and Methods of Preparation and Use of the Same
Application: 62/678,980 →
Deuterated Alvocidib and Alvocidib Prodrugs
Application: 62/688,140 →
Salts of Axl Kinase Inhibitors and Methods of Preparation and Use of the Same
Application: 62/688,161 →
Cyclin-Dependent Kinase Inhibitors in Combination with Anthracyclines for Treatment of Cancer
Application: 62/688,228 →
Axl Kinase Inhibitors and Methods of Use Thereof
Application: 62/695,609 →
Salts of Axl Kinase Inhibitors and Methods of Preparation and Use of the Same
Application: 62/698,638 →
Methods for Monitoring Tumor Lysis Syndrome
Application: 62/745,269 →
Materials and Methods for Treating Cancer
Application: 62/753,712 →
Salts of Axl Kinase Inhibitors and Methods of Preparation and Use of the Same
Application: 62/760,882 →
Axl Inhibitors for Treating Ovarian Cancers and Ascites
Application: 62/767,475 →
CDK9 Inhibitors and Polymorphs Thereof for Use as Agents for Treatment of Cancer
Application: 62/775,303 →
Methods for Treating Castration-Resistant Prostate Cancer
Application: 62/776,985 →
Salts of Axl Kinase Inhibitors and Methods of Preparation and Use of the Same
Application: 62/778,856 →
Axl Kinase Inhibitors and Polymorphs Thereof for Treatment of Cancers
Application: 62/813,705 →
Treatment of Acute Myeloid Leukemia (Aml) with Venetoclax Failure
Application: 62/821,342 →
PKM2 Modulators and Methods for Their Use
Application: 62/822,700 →
Compositions Comprising PKM2 Modulators and Methods of Treatment Using the Same
Application: 62/822,751 →
Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof
Application: 62/870,415 →
Treatment of Previously Treated Cancers
Application: 62/871,540 →
Treatment of Previously Venetoclax-Treated Cancers
Application: 62/871,665 →
Methods for Monitoring Tumor Lysis Syndrome
Application: 62/871,799 →
Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
Application: 62/871,934 →
Compositions Comprising PKM2 Modulators and Methods of Treatment Using the Same
Application: 62/875,940 →
Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof
Application: 62/888,149 →
Methods for Treating Castration-Resistant Prostate Cancer
Application: 62/909,147 →
Axl Inhibitor Formulations
Application: 62/910,709 →
Methods for Treating Castration-Resistant and Castration-Sensitive Prostate Cancer
Application: 62/926,390 →
Compositions Comprising PKM2 Modulators and Methods of Treatment Using the Same
Application: 62/926,417 →
Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitors and Uses Thereof
Application: 62/934,167 →
Combination Therapies for Treatment of Myelodysplastic Syndrome
Application: 62/944,339 →
2-Aminobenzonitrile Derivatives as NEK2 Inhibitors
Application: 62/968,033 →
Treatment of Previously Treated Cancers
Application: 63/029,938 →
Treatment of Previously Venetoclax-Treated Cancers
Application: 63/029,950 →
Combination Therapies for Treatment of Myelodysplastic Syndrome
Application: 63/037,553 →
Treatment of Cancer
Application: 63/037,561 →
Treatment of Cancer
Application: 63/037,567 →
Alk-5 Inhibitors and Uses Thereof
Application: 63/123,894 →
Forms And Formulations Of A Tyrosine Kinase Non-Receptor 1 (TNK1) Inhibitor
Application: 63/133,983 →
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 16, 2007
From: AVENTIS PHARMACEUTICALS INC.
To: HMR PHARMA INC.
Reel/Frame 020119/0606 →
Change of Name Nov 29, 2007
From: HMR PHARMA INC.
To: AVENTIS HOLDINGS INC.
Reel/Frame 020174/0006 →
Assignment of Assignor's Interest Mar 2, 2010
From: AVENTIS HOLDINGS INC.
To: AVENTISUB II INC.
Reel/Frame 024006/0487 →
Assignment of Assignor's Interest Jun 3, 2011
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 026384/0174 →
Assignment of Assignor's Interest Jun 3, 2011
From: BEARSS, DAVID J.; VANKAYALAPATI, HARIPRASAD; MOLLARD, ALEXIS; WARNER, STEVEN L.
To: UNIVERSITY OF UTAH
Reel/Frame 026384/0258 →
Assignment of Assignor's Interest Oct 15, 2013
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 031405/0665 →
Assignment of Assignor's Interest Oct 15, 2013
From: HO, KOC-KAN; XU, YONG; SAUNDERS, MICHAEL DAVID; LIU, XIAOHUI
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 031405/0507 →
Assignment of Assignor's Interest Dec 17, 2014
From: WARNER, STEVEN L; BEARSS, DAVID J
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 034528/0591 →
Assignment of Assignor's Interest Jun 16, 2015
From: SIDDIQUI-JAIN, ADAM; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 035845/0954 →
Assignment of Assignor's Interest Jun 16, 2015
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 035845/0932 →
Assignment of Assignor's Interest Oct 16, 2015
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 036808/0975 →
Assignment of Assignor's Interest Oct 16, 2015
From: BEARSS, DAVID J.; WARNER, STEVEN L.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 036809/0001 →
Security Interest Nov 17, 2016
From: TOLERO PHARMACEUTICALS, INC.
To: SUMITOMO DAINIPPON PHARMA CO., LTD.
Reel/Frame 040362/0884 →
Assignment of Assignor's Interest May 5, 2017
From: WARNER, STEVEN L.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 042418/0427 →
Assignment of Assignor's Interest Aug 30, 2017
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 043450/0729 →
Assignment of Assignor's Interest Aug 30, 2017
From: SIDDIQUI-JAIN, ADAM; SEENISAMY, JEYAPRAKASHNARAYANAN
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 043725/0382 →
Assignment of Assignor's Interest Dec 20, 2017
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 044450/0784 →
Assignment of Assignor's Interest Apr 24, 2018
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; WARNER, STEVEN L.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045622/0474 →
Assignment of Assignor's Interest Apr 24, 2018
From: SIDDIQUI-JAIN, ADAM; PETERSON, PETER W.; WHATCOTT, CLIFFORD J.; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045622/0335 →
Assignment of Assignor's Interest Aug 1, 2018
From: SIDDIQUI-JAIN, ADAM; WARNER, STEVEN L.; FLYNN, PAUL; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 046530/0097 →
Assignment of Assignor's Interest Sep 3, 2018
From: KENDERIAN, SAAD J.; KAY, NEIL E.; SAKEMURA, REONA
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 046772/0477 →
Assignment of Assignor's Interest Sep 21, 2018
From: SIDDIQUI-JAIN, ADAM; WARNER, STEVEN L.; FLYNN, PAUL; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 046940/0352 →
Assignment of Assignor's Interest Sep 21, 2018
From: WARNER, STEVEN L.; FOULKS, JASON MARC
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 046940/0337 →
Assignment of Assignor's Interest Oct 5, 2018
From: BEARSS, DAVID J.; WARNER, STEVEN L.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 047086/0203 →
Assignment of Assignor's Interest Jan 8, 2019
From: SIDDIQUI-JAIN, ADAM; WARNER, STEVEN L.; FLYNN, PAUL; BEARSS, DAVID J.
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 048025/0706 →